• Français (FR)
  • English (UK)
  • Home
  • Company
    • About us
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
      • Partnerships
  • Nox Science
    • NOX Enzymes
      • NADPH Oxidase
      • NOX Enzyme Family
      • NOX Expression
    • NOX and Disease
      • Oxidative Stress and Disease
      • Physiological Functions of NOX
      • Fibrotic diseases
      • Neurodegenerative diseases
      • Cardiovascular diseases
    • Publications
  • Pipeline
    • Setanaxib
    • Preclinical NOX1 program
    • Research programs
  • Investors
    • Stock information
    • Analyst coverage
    • Contribution project
      • Press release
      • Project presentation
      • Documentation
      • Shareholders general meeting
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Events and presentations
    • Regulated information
      • Financial information
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2015
        • 2014
      • Other regulated information
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
      • Governance
      • OCABSA warrants
    • Shareholder information
      • Shareholders’ meetings
        • 2021
        • 2020
        • 2019
          • AGM of June 13, 2019
          • AGE of January 2019
        • 2018
          • AGM of june 13, 2018
        • 2017
          • AGM of June 15, 2017
          • AGM of February 28, 2017
        • 2016
        • 2015
        • 2014
      • Agenda
  • News and Events
    • Press releases
    • Events and presentations
    • Media
      • Press clippings
      • Interviews
  • Contacts
  • Capital Increase
  • Investors /
  • Press releases /
  • 2020

Press release

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
2020-12-08 - 07:00

Genkyotex’s setanaxib granted Orphan Drug Designation by the European Commission for the treatment of PBC

2020-11-03 - 15:15

Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex

2020-10-22 - 18:30

Genkyotex provides business update and reports cash position at September 30, 2020

2020-10-20 - 18:00

Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC

2020-09-17 - 18:00

Genkyotex announces first-half 2020 results and business update

2020-09-14 - 18:00

Genkyotex announces the enrollment of the 1st patient in the Phase 2 trial of setanaxib in idiopathic pulmonary fibrosis (IPF)

2020-08-13 - 07:00

Genkyotex announces agreement for Calliditas Therapeutics to acquire controlling interest in Genkyotex SA

2020-07-23 - 18:02

Genkyotex provides business update and reports cash position at June 30, 2020

2020-06-30 - 17:45

Genkyotex announces the dosing of the first subjects in its Phase 1 study with high-dose setanaxib

2020-06-18 - 07:00

Genkyotex provides new clinical data from the PBC Phase 2 trial providing further evidence of the anti-fibrotic activity of setanaxib

2020-05-13 - 18:00

Genkyotex receives approval from the ANSM to initiate a Phase 1 clinical study with high-dose setanaxib

2020-04-23 - 18:00

Genkyotex provides business update and reports cash position at March 31, 2020

2020-03-03 - 18:38

Genkyotex’s setanaxib significantly improves immunotherapy including checkpoint inhibitors in multiple preclinical cancer models

2020-02-27 - 18:00

Genkyotex announces 2019 annual financial results and provides corporate update

2020-02-06 - 20:30

Genkyotex raises €4.9 million in its rights issue

2020-02-04 - 17:45

Genkyotex announces its financial calendar for 2020

2020-01-17 - 07:00

Genkyotex launches a rights issue for a maximum amount of €6.13 million

2020-01-16 - 19:30

Genkyotex provides business update and reports gross cash position at December 31, 2019

2020-01-13 - 17:00

Half-yearly report on Genkyotex’s liquidity contract with Kepler Cheuvreux

  • Stock information
  • Analyst coverage
  • Contribution project
    • Press release
    • Project presentation
    • Documentation
    • Shareholders general meeting
  • Press releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
  • Events and presentations
  • Regulated information
    • Financial information
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2015
      • 2014
    • Other regulated information
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Governance
    • OCABSA warrants
  • Shareholder information
    • Shareholders’ meetings
      • 2021
      • 2020
      • 2019
        • AGM of June 13, 2019
        • AGE of January 2019
      • 2018
        • AGM of june 13, 2018
      • 2017
        • AGM of June 15, 2017
        • AGM of February 28, 2017
      • 2016
      • 2015
      • 2014
    • Agenda

Ask us your questions

Suscribe to Newsletter

  • Legal terms

Back to Top

© 2021 genkyotex.com